CymitQuimica logo

CAS 138071-82-6

:

Gadobutrol

Description:
Gadobutrol is a gadolinium-based contrast agent primarily used in magnetic resonance imaging (MRI) to enhance the visibility of internal structures. It is a paramagnetic compound, which means it has unpaired electrons that enhance the magnetic properties of tissues during imaging. Gadobutrol is characterized by its high relaxivity, allowing for improved contrast in MRI scans. It is a non-ionic, water-soluble compound, which contributes to its safety profile and minimizes the risk of adverse reactions. The substance is stable under physiological conditions and is excreted primarily through the kidneys, making it suitable for patients with normal renal function. Gadobutrol is also known for its low osmolality, which reduces the likelihood of discomfort or adverse effects during administration. As with other gadolinium-based agents, there is a risk of nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, necessitating careful screening before use. Overall, Gadobutrol is valued for its efficacy and safety in enhancing MRI imaging.
Formula:C18H31GdN4O9
InChI:InChI=1/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3/t14-,15-;/s2
InChI key:InChIKey=ZPDFIIGFYAHNSK-ZCTZICQLNA-K
SMILES:C(O)[C@H]1[N]23[Gd+3]45678([N](CC2)(CC[N]4(CC[N]5(CC3)CC(=O)[O-]6)CC(=O)[O-]7)CC(=O)[O-]8)[OH][C@@H]1CO
Synonyms:
  • (10-((1RS,2SR)-2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-))gadolinium
  • (SA-8-1425362′5′)-[rel-10-[(2R,3S)-2-(Hydroxy-κO)-3-hydroxy-1-(hydroxymethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-κN<sup>1</sup>,κN<sup>4</sup>,κN<sup>7</sup>,κN<sup>10</sup>,κO<sup>1</sup>,κO<sup>4</sup>,κO<sup>7</sup>]gadolinium
  • Gadobutrol [INN]
  • Gadograf
  • Gadolinium, (10-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-N1,N4,N7,N10,O1,O4,O7)-
  • Gadolinium, [10-[2-(hydroxy-κO)-3-hydroxy-1-(hydroxymethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-κN<sup>1</sup>,κN<sup>4</sup>,κN<sup>7</sup>,κN<sup>10</sup>,κO<sup>1</sup>,κO<sup>4</sup>,κO<sup>7</sup>]-, [SA-8-1425362′5′-(R*,S*)]-
  • Gadolinium, [rel-10-[(2R,3S)-2-(hydroxy-κO)-3-hydroxy-1-(hydroxymethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-κN<sup>1</sup>,κN<sup>4</sup>,κN<sup>7</sup>,κN<sup>10</sup>,κO<sup>1</sup>,κO<sup>4</sup>,κO<sup>7</sup>]-, (SA-8-1425362′5′)-
  • Gadovist
  • Protovist
  • Zk 135079
  • See more synonyms
Sort by

Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 3 products.
  • Gadobutrol

    CAS:
    Formula:C18H31GdN4O9
    Molecular weight:604.72

    Ref: 4Z-G-3130

    5mg
    To inquire
    10mg
    To inquire
    25mg
    To inquire
    50mg
    To inquire
    100mg
    To inquire
  • Gadavist

    CAS:
    <p>Gadavist is a gadolinium-based contrast agent that is used in radiology to visualize the brain and other organs. Gadavist is injected intravenously and accumulates in the tissues, where it can be detected by MRI. Gadavist has been shown to be safe for use in humans at doses up to 7.5 mg/kg, and has been approved for use in Europe. The mechanism of action of gadobutrol is not fully understood, but it is thought that gadobutrol binds to mitochondria, which affects their membrane potential.</p>
    Formula:C18H31GaN4O9
    Purity:Min. 95%
    Molecular weight:517.2 g/mol

    Ref: 3D-NFA07182

    5g
    695.00€
    10g
    1,053.00€
    25g
    1,861.00€